11:40 PM
 | 
Feb 27, 2018
 |  BC Extra  |  Company News

MedImmune spins out autoimmune play Viela

Editor's Note: This article was updated on Feb 28, 2018 at 3:00 PM PST

MedImmune LLC is spinning out six compounds into severe autoimmune disease play Viela Bio Inc. (Gaithersburg, Md.). Bing Yao, who is head of the AstraZeneca plc (LSE:AZN; NYSE:AZN) subsidiary’s Respiratory, Inflammation & Autoimmunity (RIA) Innovative Medicines unit, will become CEO of the newco. Jorn Drappa, VP of RIA clinical development, will be Viela's head of R&D and CMO.

Yao told BioCentury that MedImmune had produced more molecules than it could fully develop, and chose to spin out some into a new company to better realize the candidates' potential. He added that Viela's development...

Read the full 444 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >